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In the 1980s the outlook for patients with the acquired immunodeﬁciency syndrome (AIDS) and critical illness was poor. Since
then several studies of outcome of HIV+ patients on ICU have shown improving prognosis, with anti-retroviral therapy playing
a large part. We retrospectively examined intensive care (ICU) admissions in a large HIV unit in London. Between April 2001
and April 2006 43 patients were admitted to the ICU. The mean age of patients was 44 years and 74% were male. Fifty-six
percent of admissions were receiving anti-retroviral therapy and 44% had an AIDS deﬁning diagnosis. The median CD4 count
was 128cells/mL and the median APACHE II score was 21. The commonest diagnostic ICU admission category was respiratory
disease. This group experienced higher mortality despite slightly lower APACHE II scores, though this did not achieve statistical
signiﬁcance. The follow up period was one year or until April 2007, when data were censored. ICU mortality was 33%, in hospital
mortality was 51% and overall mortality at the end of the study period was 67%. Median survival was 1008 days. The CD4 count
did not predict long-term survival, although the sample size was too small for this to be conclusive.
1.Introduction
In the 1980s, the outlook for patients with the acquired im-
munodeﬁciency syndrome (AIDS) and critical illness was
poor [1, 2], and intensive care for these patients was felt in-
appropriate [3, 4]. Most studies showed the worse survival
thelowertheCD4count[5–10].TheprognosisofHIV-infec-
tion has improved dramatically with highly active antiretro-
viral therapy (HAART) [11–13]. Survival of HIV+ individ-
uals admitted to intensive care has now improved, the
case mix has changed and CD4 count at admission relat-
es less to outcome [14–21]. We, in combination with others,
have previously published our intensive care experience with
HIV infected patients from the mid 1990s [7]. Survival was
shorter with CD4 count <100cells/mL. Few of the published
studies, however, have followed up patients long term [16,
22], and these only recruited up until 1999.
In recent years, the long-term prognosis of HIV+ indivi-
duals has continued to improve. With longer survival and
more patients on treatment, the cohort of HIV+ patients has
increased in size. In the UK, still one-third of patients
are diagnosed with advanced HIV disease (CD4 count
<200cells/mm3). Therefore, we undertook a service review
to examine usage of the ICU facility in our hospital by HIV+
patients. We have investigated the numbers of admissions,
case mix, and long-term survival following intensive care
unit (ICU) admission during recent years in a large London
unit.
2. Methods
The Chelsea and Westminster Hospital in South West Lon-
don provides care for over 5000HIV-infected individuals,
one of the largest cohorts in the UK. We conducted a retro-
spective review of electronic ICU records of known HIV+
patients of our hospital who were admitted to the ICU bet-
ween April 1st, 2001 and April 1st, 2006. All of the patients
included in this study were already under the care of the
HIV/GUM department for their HIV disease. The hospital
ethics committee was consulted and deemed formal ethical
review unnecessary. Data collected were age at admission,
sex, race, risk factor for HIV acquisition, receipt of anti-
retroviral therapy, admission diagnosis, reason for ICU2 Interdisciplinary Perspectives on Infectious Diseases
Table 1:Characteristicsofthe43patientsincludedinthisstudy.Thesecondcolumnispercentage,unlessstatedotherwise.IQR:interquartile
range; ART: antiretroviral therapy; MSM: men who have sex with men.
Absolute numbers Percentage (%) or IQR
Median age (IQR) 44 (40–60)
Male 32 (73%)
Race
White 23 (53.5%)
Black 10 (23.6%)
Asian 4 (9.3%)
Other 2 (4.7%)
Unknown 4 (9.3%)
HIV risk factor
Heterosexual 15 (34.9%)
MSM 23 (53.5%)
Injection drug use 3 (7%)
Unknown 2 (4.7%)
On ART
Yes 24 (55.8%)
No 13 (30.2%)
Unknown 6 (14%)
Median CD4 (IQR) 128 (9–627)
Median APACHE II (IQR) 21 (10–38)
AIDS-deﬁning diagnosis at time of ICU admission 19 (44%)
admission, CD4 count, HIV viral load, acute physiology and
chronic health evaluation II (APACHE II) score, length of
stay, organs systems supported, and outcome. Admissions
were deﬁned as AIDS-related if prompted by an AIDS deﬁn-
ing illness [23]. Standard deﬁnitions were used for sepsis and
septic shock [24]. Followup lasted until April 1st, 2007, a
minimum followup period of one year for all patients.
2.1. Data Analysis. Cox regression was used to correlate var-
iables of interest with outcome. Kaplan-Meier analysis and
log rank test were used to examine long-term survival. The
Wilcoxon rank sum test was used to compare CD4 counts
between groups. Stata 10 and r software were used for
analysis. A signiﬁcance level of 0.05 was used throughout.
3. Results
3.1. Descriptive Analysis. During the study period, 43 pa-
tients were admitted to the ICU, each on one occasion. All
patients were known to be HIV+ at the time of ICU admis-
sion, there were no diagnoses made on the ICU during the
study period. Characteristics of the patients in this study are
shown in Table 1.
3.2. Reason for Admission to ICU and Usage. The reasons for
admission to ICU by category and subsequent outcome are
shown in Table 2. All of the patients in this study had only
one admission to ICU. The mean length of ICU stay was 10
days (median 6 days; range 1 to 47).
Thirty-three patients (78.7%) had respiratory support,
26 (62%) underwent tracheal intubation and mechanical
ventilation, and seven (16.7%) had noninvasive ventilation.
Twenty-three patients (56%) had cardiovascular support
with inotropes (data missing for two patients). Eleven pa-
tients (26.8%) had renal replacement therapy (data missing
for two patients).
3.3. Diagnosis. A wide variety of diagnoses were made
(Table 3). Seven patients had more than one diagnosis made
(not including patients with organ failure as part of a sepsis
syndrome or neutropaenic sepsis occurring on the back-
ground of chemotherapy for malignancy). These were
Castleman’s disease/PCP (at presentation), Burkitt’s lym-
phoma/pneumonia (at presentation), PCP/pulmonary oed-
ema, pneumonia/pontine haemorrhage, tuberculous arthri-
tis/renal failure (unexplained), anal carcinoma/renal failure
(drug related), and multiple myeloma/non-Hodgkin’s lym-
phoma.
Nineteen admissions (44%) were for AIDS-related diag-
noses (according to 1993 CDC criteria). However, 31 admis-
sions (72%) in total were for HIV-related diagnoses, this
includes the 19 AIDS-related admissions plus further 12
patients with serious infections but CD4 counts greater than
200. Twelve patients were admitted to ICU for reasons not
directly related to HIV infection. These were pneumoth-
orax/threatened airway, pancreatitis (2 patients), GI bleed
(2 patients), liver failure, renal failure (2 patients), status
epilepticus, deliberate drug overdose, adhesional bowel
obstruction on a background of ulcerative colitis, and neu-
tropaenic sepsis related to chemotherapy for anal carcinoma
(considered not related to HIV).Interdisciplinary Perspectives on Infectious Diseases 3
Table 2: Primary reasons for ICU admission and outcomes. Numbers are absolute values (percentage). HR: hazard ratio for death in that
group. All 95% conﬁdence intervals for hazard ratios overlap 1.
Number admitted ICU mortality HR Hospital mortality HR Mortality at end of followup HR
Respiratory 16 7 (43.8%) 1.3 11 (68.8%) 1.7 12 (75%) 1.2
GI 4 1 (25%) 0.8 2 (50%) 1 3 (75%) 1.1
Neurological 4 1 (25%) 0.8 2 (50%) 1 3 (75%) 1.1
Sepsis 12 1 (25%) 0.8 4 (33.3%) 0.6 8 (66.7%) 1
Other 7 2 (28.6%) 0.9 3 (42.9%) 0.8 3 (42.9%) 0.6
Total 43 14 (32.5%) 22 (51.2%) 29 (67.4%)
Table 3: Diagnoses resulting in the need for ICU admission among
the patients included in this study.
Diagnosis No.
PCP 6
Pneumonia 5
TB 3
Neurological infection∗ 2
Septic shock 8
Neutropaenic sepsis# 5
Malignancy¶ 4
GI bleed 2
Pancreatitis 2
Other§ 6
∗Toxoplasmosis and Pneumococcal meningitis.
#Allrelatedtochemotherapyformalignancy;4patientshadlymphomaand
1 had anal carcinoma.
¶Further 9 patients were admitted for another reason but with a back-
ground of malignancy.
§One patient with pneumothorax, 1 with liver failure, 1 with renal failure,
1with status epilepticus,1 withulcerative colitis,and 1 with drugoverdose.
3.4.CD4CountandAntiretroviralTherapy. ThemedianCD4
count was 128cells/mL (range 4 to 958). In the 19 patients
(44%)whowereadmittedtoICUafterdiagnosisofanAIDS-
deﬁning illness, median CD4 count was lower; 58 versus
210cells/mL (P<0.001). Median CD4 count in patients
with any HIV-related admission (not only AIDS) was lower
compared with patients admitted for reasons unrelated to
HIV infection (100 versus 242cells/mL, P<0.001).
Twenty-four patients of 37 patients for whom data were
available were on HAART before ICU admission. Median
CD4 counts in patients on HAART and not on HAART were
188cells/mL and 89cells/mL, respectively. Of the 24 patients
on HAART, 16 (66.6%) were virologically suppressed. Eight
patients had detectable HIV RNA in plasma; four of these
had a viral load less than 400copies/mL.
3.5. Survival. Mortality rates throughout the study period
are shown in Table 2. Fourteen patients died on the ICU;
the median time to death on ICU was 8.5 days (mean 9.8
days, IQR 2 to 16 days; range 1 to 23 days). Eight patients
survived after ICU admission but died in hospital; median
time to death for this group was 30 days from the date of
ICU admission (mean 37.1 days; range 3 to 77). Twenty-
two patients (51%) died in hospital. Median time to death
of those who survived to hospital discharge but died during
followup (seven patients) was 352 days from ICU admission
(mean 295.7 days; range 81 to 565). Median time to death
from ICU admission for nonsurvivors was 20 days (mean
86.3 days).
Mortality was higher than average in patients with a res-
piratory diagnosis (Table 2) although the median APACHE
II score was lower in the respiratory group (17 versus 26).
Adjustment for this, however, showed no signiﬁcant diﬀer-
ence in mortality between the two groups. Mortality among
patients requiring invasive ventilation was slightly, though
not signiﬁcantly, higher than total mortality (P = 0.108).
We did not observe any association between CD4 count
and survival in this population (P = 0.77). Figure 1 shows
Kaplan-Meier analysis of survival for patients with a CD4
count greater than or less than 100. There was no diﬀerence
in long-term survival between patients with CD4 counts
above or below 100cells/mL (log rank test, P = 0.56). Anal-
ysis using CD4 count cut-oﬀs of 50 and 200cells/mL gave
similar results.
There was a nonsigniﬁcant trend to increasing mortality
withincreasing APACHE II score, hazardratio 1.04 per point
increase in APACHE II score, P = 0.056 (a doubling of mor-
tality with 17 point increase in APACHE II score). No other
variables were signiﬁcantly associated with mortality; there-
fore, multivariate analysis was not performed.
The median followup for the study was 1008 days (range
1–2015 days). Overall, 29 (67.4%) patients died during the
study period. Median survival in those who died was 20
days after ICU admission (range 1–565 days). Twenty-six of
the 29 patients who died had died by one year of followup.
Although early mortality was high, all patients that survived
more than two years after the date of ICU admission were
alive at the end of the study period.
4. Discussion
It is striking that, despite coming from a large unit, the num-
ber of patients admitted to ICU during a ﬁve-year period
was low, only 43. Because of this small number, it is diﬃcult
to make generalisations to a larger population, however it is
clear that the burden placed on the ICU facility by our large
HIV+populationisnotgreat.Ourunittookpartinanearlier
study on ICU usage by HIV+ patients in the same region [7].
Whilst it may be diﬃcult to make direct comparisons bet-
ween the studies, ICU mortality was 33% in each study4 Interdisciplinary Perspectives on Infectious Diseases
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Figure 1: Survival of HIV+ patients admitted to ICU by CD4 count
category greater or less than 100. P = 0.56 by log rank test. Analysis
using a CD4 cut-oﬀ of 200 or 50 gave a similar result.
despite a lower median APACHE II score in the earlier study
by Gill et al., 15 versus 21 in this study. Dickson et al. have
published the recent experience of another ONE of the ICUs
involved in the original study; median APACHE II score was
18 and ICU mortality 23% [14]. The fact that mortality re-
mains the same in our study whereas APACHE II score was
higher may mean that, matched for severity of illness, out-
come has improved and sicker patients are admitted to ICU
during the later period. The median CD4 was 40 during the
period 1993–1997 and 128 in this study. This may reﬂect
the increased proportion of patients receiving HAART
(24.5% compared with 56%) though other factors cannot be
excluded.
Respiratory illness remains the most common reason for
ICU admission in the era of HAART, though as a proportion
ofthetotaladmissionsitsfrequencyhasdroppedfrom51.2%
[7] to 37.2%. The rate of admission for pulmonary diagnosis
(particularly PCP) is falling in other series but remains a
common reason for ICU admission in HIV+ patients [16,
17]. In particular, admission for PCP has fallen, whereas
admission for respiratory failure not due to PCP has risen in
this study compared with the pre-HAART era. Two patients
hadcomplicationsofliverdisease,varicealhaemorrhage,and
liver failure. Although conclusions cannot be drawn from
such small numbers, our only patient with liver failure died
on ICU, consistent with the ﬁndings of Dickson et al. where
liver failure in the context of HIV had a poor ICU prognosis
[14]. Liver disease is making an increasing contribution to
mortality in HIV+ patients [25].
Therewerealargenumber(28%)ofadmissionsforsepsis
in this study period. Despite the small population size, this is
likely to represent an increase from 10.5% in 1993–1997 [7].
This is consistent with trends in US death certiﬁcate report-
edinthelate1990sshowinganincreaseindeathsfromseptic
aemia in HIV+ patients [26]. ICU mortality from sepsis was
25% in this study, lower than in 1993–1997 (50%).
The use of renal replacement therapy increased from
1.5% of patients in the 1993–1997 period to 26.8% of pa-
tients in this cohort, partially (though not fully) accounted
for by the increased number of patients with sepsis who had
renal replacement therapy. Renal failure is more common in
HIV+ patients than other groups and it is associated with an
increase in mortality [27]. The increase in use of renal re-
placement therapy perhaps reﬂects an underlying trend to
treat these patients more aggressively in the light of their im-
proved long-term prognosis.
Interestingly the majority of patients who were admitted
to ICU were admitted for reasons directly related to HIV in-
fection (72%). Of those who were not, at least ﬁve had medi-
cal conditions caused or exacerbated by drug or alcohol mis-
use (liver failure, two GI bleeds, one case of pancreatitis and
deliberate drug overdose). Although not directly HIV relat-
ed these admissions (12% of all admissions) underline the
signiﬁcant burden of psychiatric co-morbidity occurring in
the context of HIV infection.
In our study, HAART use and CD4 count at ITU admis-
sion were not related to long-term survival. However, our
population is too small to adequately interrogate this diﬀer-
ence. There may be other reasons for changes in CD4 count
and/or survival over time, such as improvements in nutri-
tion, prophylaxis or other aspects of care. Two larger studies
with long followup did detect an inﬂuence of HAART on
survival [16, 22]. Four of our patients appeared to be failing
HAART; a shortcoming of this study is that we did not
collect the reasons for this. Median long-term survival in this
study was 1008 days, and no patient who survived for more
than 2 years after ICU admission died during the study
period. Two recent studies have also reported encouraging
long-term survival [16, 22].
This study has signiﬁcant shortcomings. The population
issmallmakingitdiﬃculttogeneralisetolargerpopulations.
Data on antiretroviral therapy are incomplete, and duration
andtypeofregimewerenotcollected.Nevertheless,thesmall
size of the population in this study drawn from such a large
unit (5000 patients) is indicative of the improved health of
HIV+ patients in the era of HAART. Despite its size and ret-
rospective nature, our study adds to the growing body of evi-
dencethatICUcareisnotfutileeveninthesettingofadvanc-
ed HIV disease.
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